復發性卵巢癌的第二次減積術

Secondary Cytoreduction in Recurrent Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 趙德讓(Tai-Jong Chao) ； 柯天龍(Tien-Lung Ko) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2007年1期 (2007/04) Pp. 24-28

https://doi.org/10.7010/JGO.200704.0024

摘要

晚期卵巢癌，復發率很高，一旦復發，能存活的機率很低，過去多以第二、三線的化學藥物，或放射線治療，或腹腔內化學藥物治療，當作延長生命治療方式。經過多年研究，對經過選擇的復發病患，行第二次減積手術，能有較多機會切除所有時病灶，結果可增長生存率和改善生活品質。

關鍵字

卵巢癌 ； 第二次減積術

並列摘要

The role of primary cytoreductive surgery in ovarian cancer is well established. Minimal residual disease translates to improved response to chemotherapeutic treatment and prolonged survival, Most of advanced stage ovarian cancer patients will ultimately develop recurrent disease after completing primary therapy. These patients are often treated with 2 or 3 line chemotherapeutic agents. The role of secondary cytoreduction in recurrent ovarian cancer is uncertain. After review of literature, the available data suggest a benefit for secondary surgical cytoreduction in recurrent ovarian cancer. However, it is not known if a salvage strategy combining surgery and multiagent chemotherapy regimens will have a survival benefit over chemotherapy alone, Further investigation is warranted.

並列關鍵字

Ovarian cancer ； Secondary cytoreduction